Related Experiment Video
Updated: Apr 17, 2026

08:17
Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
Published on: September 22, 2017
20.4K
Rhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy
Tracy N Jaggers1, Ana Ripolles-Garcia1, Ala Moshiri2
1Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616.
Summary
Researchers developed a new nonhuman primate model for Autosomal Dominant Optic Atrophy (ADOA) using rhesus macaques with an OPA1 gene mutation. This model shows key disease features like retinal nerve fiber layer thinning and ganglion cell loss, aiding ADOA research.
Area of Science:
- Ophthalmology
- Genetics
- Neuroscience
Background:
- Autosomal dominant optic atrophy (ADOA) is an inherited optic neuropathy.
- Mutations in the OPA1 gene are the primary cause of ADOA.
- Existing models do not fully recapitulate the human disease's complexity.
Purpose of the Study:
- To establish and characterize a novel nonhuman primate (NHP) model of ADOA.
- To investigate the pathogenesis of ADOA using this NHP model.
- To provide a translational platform for testing therapeutic interventions.
Main Methods:
- Genetic sequencing to identify OPA1 mutation in rhesus macaques.
- Ocular examinations, spectral-domain optical coherence tomography, and fundus photography.
- Electroretinography, histopathology, immunohistochemistry, and transmission electron microscopy (TEM).
Main Results:
- Established a rhesus macaque model heterozygous for the OPA1A8S missense mutation.
- Documented retinal nerve fiber layer thinning, retinal ganglion cell loss, and dysfunction.
- Observed OPA1 mislocalization, reduced mitochondrial density, and ultrastructural changes in affected macaques.
Conclusions:
- The NHP model exhibits key pathological features of human ADOA.
- Phenotypic variability in the model mirrors clinical heterogeneity in patients.
- This model offers a valuable preclinical tool for ADOA therapeutic development.

